

بسم الله الرحمن الرحيم

الآية

قال تعالى:

{لَا يُكَلِّفُ اللَّهُ نَفْسًا إِلَّا وُسْعَهَا لَهَا مَا كَسَبَتْ وَعَلَيْهَا مَا اكْتَسَبَتْ رَبَّنَا لَا تُؤَاخِذْنَا إِنْ نَسِينَا
أَوْ أَخْطَاْنَا رَبَّنَا وَلَا نَحْمِلْ عَلَيْنَا إَصْرًا كَمَا حَمَلْتَهُ عَلَى الَّذِينَ مِنْ قَبْلِنَا رَبَّنَا وَلَا تُحَمِّلْنَا مَا لَا
طَاقَةَ لَنَا بِهِ وَاعْفُ عَنَّا وَارْحَمْنَا أَنْتَ مَوْلَانَا فَانصُرْنَا عَلَى الْقَوْمِ الْكَافِرِينَ }

صدق الله العظيم

سورة البقرة الآية 286

Dedication

To the candle which burns to light my life.....

My Mother

To the one whom I live for making his dreams true..

My Father

To the one who is great source for motivation and inspiration

My Husband

To those have made it possible

My teachers

To whom encourage me

My brothers and friends

Acknowledgment

First of all thanks for Allah, who gave me the power and willingness to complete this research. I would like also to thank my supervisor Dr.Fathelrahman Gameel for his support and instructions that helped me to finish this work.

I would like to thank Dr. Munsoor Mohammed Munsoor and the head department of haematology Mudathir Abdelrahim in Sudan University of Science and Technology for their great help.

Special thanks to my colleagues Zobiya, Hind and Maye.

I acknowledge with special appreciation the support of the staff of East Nile Modern hospital.

Finally I would like to thank everyone who supported and stand beside me in every step of this research.

Abstract

This is descriptive cross sectional study which was carried out in Khartoum state. To assess the effect of chronic kidney disease in platelet count and indice. The study includes 75 diagnosed chronic kidney disease patients and 75 age and sex matched healthy individuals as control group, Blood samples were collected and tested for platelet count, mean platelet volume, platelet distribution width, platelet large cell ratio and creatinine level. The study revealed that insignificant difference in platelet count, mean platelet volume, platelet distribution width and platelet large cell ratio in chronic kidney diseases patients($274.01 \pm 102.5 \times 10^9/\text{C/L}$, $9.27 \pm 1.1\text{fl}$, $11.58 \pm 2.3\text{fl}$, and $21.07 \pm 8.0\%$ respectively) compare to control group($286.60 \pm 76.5 \times 10^9/\text{C/L}$, $9.56 \pm 0.6\text{fl}$, $11.85 \pm 1.8\text{fl}$ and $22.49 \pm 4.7\%$ respectively). There is insignificant different in platelet count ,mean platelet volume ,platelet distribution width and platelet large cell ratio in patients had serum creatinine lees than 6mg/dl ($290 \pm 112.1 \times 10^9/\text{C/L}$, $9.37 \pm 1.1\text{fl}$, $11.6 \pm 2.2\text{fl}$ and $21.51 \pm 7.7\%$ respectively) compare to patients had serum creatinine more than 6mg/dl($262.07 \pm 94.5 \times 10^9/\text{C/L}$, $9.20 \pm 1.2 \text{ fl}$, $11.56 \pm 2.5\text{fl}$, $20.76 \pm 8.4\%$ repectively). There is insignificant difference in platelet count ,mean platelet volume ,platelet distribution width and platelet large cell ratio in patients had disease less than 2 years($275.73 \pm 102.7 \times 10^9/\text{C/L}$, $9.32 \pm 1.2\text{fl}$, $11.55 \pm 2.4\text{fl}$, $21.32 \pm 8.4\%$ respectively)compare to patients had disease more than 2 years($265.85 \pm 105.6 \times 10^9/\text{C/L}$, $9.07 \pm 0.8\text{fl}$, $11.77 \pm 2.5\text{fl}$,and $19.96 \pm 8.5\%$ respectively). There is insignificant difference in platelet count ,mean platelet volume ,platelet distribution width and platelet large cell ratio in patients on hemodialysis($266.80 \pm 100.6 \times 10^9/\text{C/L}$, $9.25 \pm 1.2 \text{ fl}$,

11.67 \pm 2.5fl,and 21.00 \pm 8.2% respectively) compare to patients not on hemodialysis(284.83 \pm 106.2x10⁹C/L, 9.30 \pm 1.1fl, 11.47 \pm 2.2fl,and21.20 \pm 7.9% respectively) .the study concluded there is no effect of chronic kidney disease on platelet count and indices.

ملخص الدراسة

هذه دراسة تحليلية وصفية مقطعية، أجريت في ولاية الخرطوم، لتقييم تأثير مرض الكلى المزمن في عدد الصفائح الدموية ومؤشراتها. وشملت الدراسة 75 مريضاً مشخصاً بمرض الكلى المزمن و75 من الأفراد الأصحاء كمجموعة ضابطة مقابلين للعمر والجنس لمجموعة المرضى، تم جمع عينات الدم واختبرت لعدد الصفائح الدموية، حجم الصفائح الدموية، عرض توزيع الصفائح الدموية، ونسبة الصفائح الدموية للخلية الكبيرة ومستوى الكرياتينين. وكشفت الدراسة أنه لم يكن هناك اختلاف في عدد الصفائح الدموية، حجم الصفائح الدموية، عرض توزيع الصفائح الدموية ونسبة الصفائح الدموية للخلية الكبيرة في مرضى الكلى المزمن (102.5 ± 274.0 ، 10^9 خلية/لتر، 1.1 ± 2.27 فمتلتر، 2.3 ± 11.58 فمتلتر، 8 ± 21.07 %) على التوالي مقارنة بالمجموعة الضابطة (67.5 ± 286.60 ، 10^9 خلية / لتر، 0.6 ± 9.56 فمتلتر، 1.8 ± 11.58 فمتلتر، 4.7 ± 22.49 %) على التوالي. وأوضحت الدراسة أنه لم يكن هناك فرق في عدد الصفائح الدموية، حجم الصفائح الدموية، عرض توزيع الصفائح الدموية ونسبة الصفائح الدموية للخلية الكبيرة في مجموعة المرضى الذين كان لديهم مستوى كرياتينين أقل من 6 ملليجرام/ديسلتر (112.1 ± 29 ، 10^9 خلية/لتر، 1.1 ± 9.37 فمتلتر، 2.2 ± 11.6 فمتلتر، 7.7 ± 21.51 % على التوالي) مقارنة بالمرضى الذين لديهم مستوى كرياتينين أعلى من 6 ملليجرام/ديسلتر (94.5 ± 262.07 ، 10^9 خلية/لتر، 1.2 ± 9.20 فمتلتر، 2.5 ± 11.56 فمتلتر، 8.4 ± 20.76 %) على التوالي. وأظهرت الدراسة أنه لم يكن هناك اختلاف في عدد الصفائح الدموية، حجم الصفائح الدموية، عرض توزيع الصفائح الدموية ونسبة الصفائح الدموية للخلية الكبيرة في مجموعة المرضى الذين كان لديهم المرض لمدة أقل من سنتين (275.73 ± 102.7 ، 10^9 خلية/لتر، 1.2 ± 9.3 فمتلتر، 2.4 ± 11.54 فمتلتر، 8.4 ± 21.31 %) على التوالي مقارنة بالمرضى الذين لديهم المرض لأكثر من سنتين (105.6 ± 265.85 ، 10^9 خلية / لتر، 0.8 ± 9.06 فمتلتر، 2.5 ± 11.746 فمتلتر، 8.5 ± 19.96 %) وأشارت الدراسة أنه لم يكن هناك اختلاف في عدد الصفائح الدموية، حجم الصفائح الدموية، عرض توزيع الصفائح الدموية ونسبة الصفائح الدموية للخلية الكبيرة في المرضى الذين يقومون بغسيل الكلوي الدموي (100.6 ± 266.8 ، 10^9 خلية / لتر، 9.25 ± 1.2 فمتلتر، 2.5 ± 11.65 فمتلتر، 8.2 ± 21.00 %) على التوالي مقارنة بالذين لا يقومون بغسيل كلوي دموي (106.2 ± 284.83 ، 10^9 خلية/لتر، 1.1 ± 9.30 فمتلتر، 2.2 ± 11.4 فمتلتر، 7.9 ± 21.19 %) على التوالي. وفي ختام هذه الدراسة وجد أنه لم يكن هناك تأثير لمرض الكلى المزمن في عدد الصفائح الدموية ومؤشراتها.

List of contents

Subjects		Page No
الايه		I
Dedication		II
Acknowledgment		III
Abstract		IV
مستخلص الدراسه		VI
Contents		VII
List of table		XIII
List of figure		XIV
Abbreviation		XV
Chapter One		
introduction and Literature review		
1.1	General introduction	1
1.2	Literature review	2
1.2.1	Haematopoiesis	2
1.2.1.1	blood cells are divided into three lineages	2
1.2.1.2	Sites of haematopoiesis (human) in pre- and postnatal periods	2
1.2.1.3	Extramedullary hemopoiesis	3
1.2.2	Platelets(Thrombocyte)	3
1.2.2.1	Definition of platelet	3
1.2.2.2	Megakaryocytes (MKs) and Platelet Production	3

1.2.2.3	Ultrastructure of resting platelet:	4
1.2.2.3.1	Peripheral zone	4
1.2.2.3.2	Sol-Gel zone:	4
1.2.2.3.3	Organelle zone	4
1.2.2.4	Function of platelet	4
1.2.2.5	Process of platelet in hemostasis	5
1.2.2.5.1	Platelet adhesion	5
1.2.2.5.2	Platelet activation	5
1.2.2.5.2.1	Induction	5
1.2.2.5.2.2	Coagulation facilitation	5
1.2.2.5.2.3	Morphology change	5
1.2.2.5.2.4	GPIIb/IIIa activation	6
1.2.2.5.3	platelet aggregation:	6
1.2.2.5.4	Platelet-coagulation factor interactions	6
1.2.2.6	Symptoms of platelet disorders	6
1.2.2.7	Disorder of platelet:	7
1.2.2.7.1	Thrombocytopenia	7
1.2.2.7.1.1	Causes of Thrombocytopenia	7
1.2.2.7.1.1.1	Pseudo thrombocytopenia (artifactual)	7
1.2.2.7.1.1.2	Inherited	7
1.2.2.7.1.1.3	Congenital non-inherited	7
1.2.2.7.1.1.4	Acquired	7
1.2.2.7.1.1.5	Platelet sequestration in the spleen	8
1.2.2.7.2	Thrombocytosis (Thrombocythemia)	8
1.2.2.8	Measurement of platelet	8

1.2.2.8.1	Additional platelet parameters: mean platelet volume (MPV), platelet distribution width(PDW), platelet large cell ratio(PLCR).	8
1.2.2.9	Transfusion therapy with platelet	10
1.2.2.9.1	Indications	10
1.2.2.9.2	Collection	10
1.2.2.9.3	Storage	10
1.2.2.9.4	Delivery to recipients	11
1.2.2.10	Woundtherapy	12
1.2.3	Chronic Kidney Disease	12
1.2.3.1	The Kidneys	12
1.2.3.2	Renal anatomy	12
1.2.3.2.1	The glomerulus	12
1.2.3.2.2	The proximal convoluted tubules	13
1.2.3.2.3	The long loop of Henle	13
1.2.3.2.4	The distal convoluted tubules	13
1.2.3.2.5	Collecting ducts	13
1.2.3.3	Renal failure	13
1.2.3.4	Chronic Renal Failure (CRF) / Chronic Kidney Disease (CKD)	14

1.2.3.5	Signs and symptoms	14
1.2.3.6	Causes	16
1.2.3.7	Diagnosis	17
1.2.3.7.1	Stages	17
1.2.3.7.2	NDD-CKD vs. ESRD	19
1.2.3.8	Screening	19
1.2.3.9	Treatment	20
1.2.3.10	Prognosis	21
1.2.3.10.1	Cancer risk	21
1.2.4	Platelet abnormalities and chronic kidney disease	22
1.3	Objectives	25
1.3.1	General objective	25
1.3.2	Specific objectives	25
1.4	Rationale	26
Chapter Two		
Materials and Methods		
2.1	Study design	27
2.2	Study population	27
2.2.1	Inclusion criteria	27
2.2.2	Exclusion criteria	27
2.3	Sample collection	28
2.4	Data collection	28
2.5	Methodology	28

2.5.1	Measuring of platelet count, MPV and PDW by Sysmex KX-21N	28
2.5.1.1	Principle	28
2.5.1.2	Reagent	28
2.5.1.3	Method	29
2.5.1.4	Result calculation	29
2.5.1.5	Reference range	29
2.5.2	Count of platelet from thin blood film staining by Ral-555	29
2.5.2.1	staining principle	29
2.5.2.2	Reagents	30
2.5.2.3	Method	30
2.5.2.4	Result	30
2.5.3	Measurement Creatinine level by Roche/Hitachi cobas c systems	31
2.5.3.1	Test principle	31
2.5.3.2	Reagents	31
2.5.3.3	Method	31
2.5.3.4	Result	31
2.5.3.5	Reference range	31
2.6	Ethical consideration	32
2.7	Data analysis	32
Chapter Three		
Results		33

Chapter Four		
Discussion , Conclusion &Recommendation		
4.1	Discussion	39
4.2	Conclusion	41
4.3	Recommendations	41
References		42
Appendix	Questionnaire	53

List of Tables

Table No	Table Content	Page
(3-1)	Baseline Characteristics of the Study Population	34
(3-2)	Comparison of mean platelet count and mean platelet indices (MPV, PDW and PLCR) between cases and controls	35
(3-3)	Comparison of platelet count and platelet indices (MPV, PDW and PLCR) between patients had S.creatinine Less than 6 mg\dl and More than 6 mg\dl	36
(3-4)	Comparison of platelet count and platelet indices (MPV, PDW and PLCR) between patients had the disease less than 2 years and more than 2 years	37
(3-5)	Comparison of platelet count and platelet indices (MPV, PDW and PLCR) between patients on haemodialysis and not on haemodialysis	38

List of Figures

Figure No	Figure content	Page No
(1-1)	Platelet Distribution Width and Platelet Large Cell ratio.	10

Abbreviation

ADP	Adenosine diphosphate
ACEIs	Angiotensin converting enzyme inhibitors
ARBs	Angiotensin II receptor Blockers
ARF	Acute Renal Failure
CKD	Chronic kidney disease
CRD	Chronic renal disease
CRF	Chronic Renal Failure
CMV	Cytomegalo virus
CVD	Cerebrovascular disease
DIC	Disseminated intravascular coagulation
DMSA	Dimercaptosuccinic acid
EDTA	Ethylene diamine tetra acetic acid
ESRD	End stage renal disease
FL	Femto-liter
FGF23	Fibroblast growth factor-23
GFR	Glomerular filtration rate
GP	Glycoprotein

HELLP	Hemolysis, elevated liver enzymes, and low platelets.
HIV	Human immune deficiency virus
HSCs	Haematopoietic stem cells
HUS	Hemolytic-uremic syndrome
IgA	Immunoglobulin A
ITP	Immune thrombocytopenic purpura
MAG3	Mercaptoacetyl triglycine
MPV	Mean platelet Volume
MKs	Megakaryocytes
N	Number of sample
NDD-CKD	Non-dialysis dependent CKD
OCS	Open canalicular system
PAF-AH	Platelet activating- acetylhydrolase
PDGF	Platelet-derived growth factor
PDW	Platelet distribution width
PF4	Platelet factor 4
PLCR	Platelet large cell ratio
PLT	Platelet
PON	paraoxonase

PRP	Platelet-rich plasma
RAS	renin-angiotensin system
RBCs	Red blood cells
RRT	Renal replacement therapy
SD	Standard Deviation.
SUST	Sudan university of science and technology
SPSS	Statistical package of social science
TAR	Thrombocytopenia–absent radii
TGF	Tumor growth factor
TTP	Thrombotic thrombocytopenic purpura
VEGF	Vascular endothelial growth factor
vWF	Von willebrand